Could a simple shot replace monthly IV infusions for kidney transplant patients?

NCT ID NCT05975450

Completed Disease control Sponsor: Idelberto Badell Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether kidney transplant recipients can safely switch from monthly intravenous belatacept to weekly self-injected abatacept to prevent organ rejection. Sixteen adults who were 8-20 weeks post-transplant took part. Researchers checked how well patients could give themselves the shots, whether rejection occurred, and any serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abatacept (Orencia) subcutaneous injection
What this could lead to: If it works, this could offer kidney transplant recipients a more convenient, self-administered option to prevent organ rejection.
What could go wrong: This is a very small, early-phase trial with only 16 participants, so results may not apply broadly. The switch could increase rejection risk or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT RECIPIENT

Contacts and locations

Locations

Emory Clinic

Atlanta, Georgia, 30322, United States
Emory Hospital

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.